Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30716899 | 0.87 | LMNA (0.38) | ATML3MBTL1MAPTCHRM1LMNA | |
| SCHEMBL28934800 | 0.85 | KMT2A (0.40) | MAPTLMNAHPGDKMT2AHSD17B10 | |
| SCHEMBL29268630 | 0.85 | IDO1 (0.39) | CYP2D6POLB | |
| SCHEMBL28880210 | 0.82 | ACLY (0.35) | L3MBTL1MAPTCHRM1LMNAADRA1A | |
| SCHEMBL9101762 | 0.82 | TYR (0.43) | MAPTLMNATYRHPGDALDH1A1 | |
| SCHEMBL10560063 | 0.81 | TSHR (0.48) | L3MBTL1MAPTLMNAHPGDALDH1A1 | |
| SCHEMBL30666645 | 0.80 | LMNA (0.38) | L3MBTL1MAPTCHRM1LMNAADRA1A | |
| SCHEMBL9101570 | 0.80 | LMNA (0.38) | L3MBTL1MAPTCHRM1LMNAADRA1A | |
| SCHEMBL531432 | 0.80 | LMNA (0.47) | L3MBTL1MAPTCHRM1LMNAADRA1A | |
| SCHEMBL30667146 | 0.80 | LMNA (0.38) | L3MBTL1MAPTCHRM1LMNAADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3126339-A1 | 2,5-DISUBSTITUTED CYCLOPENTANE CARBOXYLIC ACIDS AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2017-02-08 | — | — | EP | disclosed |
| WO-2015150363-A1 | 2,5-DISUBSTITUTED CYCLOPENTANE CARBOXYLIC ACIDS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-08 | — | — | WO | disclosed |
| EP-1377542-B1 | HIV PROTEASE INHIBITORS BASED ON AMINO ACID DERIVATIVES | AMBRILIA BIOPHARMA INC (CA) | 2007-08-01 | — | — | EP | disclosed |
| EP-1803706-A1 | HIV protease inhibitors based on amino acid derivatives | Ambrilia Biopharma Inc. (CA) | 2007-07-04 | — | — | EP | disclosed |
| US-6677367-B2 | LYSINE DERIVATIVE WITH 2-AMINOSULFONYLTHIOPHENE SUBSTITUENT; ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) VIRICIDES | PHARMACOR INC. (CA) | 2004-01-13 | — | — | US | disclosed |
| EP-1377542-A1 | HIV PROTEASE INHIBITORS BASED ON AMINO ACID DERIVATIVES | Pharmacor Inc. (CA) | 2004-01-07 | — | — | EP | disclosed |
| US-6656965-B2 | In particular N-epsilon-amino acid substituted L-lysine derivatives possessing aspartyl protease inhibitory properties. | PHARMACOR INC. (CA) | 2003-12-02 | — | — | US | disclosed |
| US-20030195159-A1 | HIV protease inhibitors based on amino acid derivatives | TAIMED BIOLOGICS, INC. (TW) | 2003-10-16 | — | — | US | disclosed |
| US-6610689-B2 | Viricides | PHARMACOR INC. (CA) | 2003-08-26 | — | — | US | disclosed |
| US-6608100-B1 | N-epsilon-amino acid substituted L-lysine sulfonamide derivatives possessing aspartyl protease inhibitory properties | PHARMACOR INC. (CA) | 2003-08-19 | — | — | US | disclosed |
| US-20030144265-A1 | HIV protease inhibitors based on amino acid derivatives | TAIMED BIOLOGICS, INC. (TW) | 2003-07-31 | — | — | US | disclosed |
| US-20030119803-A1 | HIV protease inhibitors based on amino acid derivatives | TAIMED BIOLOGICS, INC. (TW) | 2003-06-26 | — | — | US | disclosed |
| US-6506786-B2 | Such as N-isobutyl-N-(4-methylbenzene-sulfonyl)-N-(N-(4-methylbenzenesulfonyl)-L -phenylalanyl)-L-lysine | PHARMACOR INC. (CA) | 2003-01-14 | — | — | US | disclosed |
| US-20020151546-A1 | HIV protease inhibitors based on amino acid derivatives | TAIMED BIOLOGICS, INC. (TW) | 2002-10-17 | — | — | US | disclosed |
| WO-2002064551-A1 | HIV PROTEASE INHIBITORS BASED ON AMINO ACID DERIVATIVES | PHARMACOR INC. (CA) | 2002-08-22 | — | — | WO | disclosed |
| US-5489501-A | MIXTURES OF TWO COORDINATION COMPOUNDS WHICH REACT TO FORM NEW COORDINATION COMPOUND WHILE CAUSING VISIBLE COLOR CHANGES | RICOH COMPANY, LTD. (JP) | 1996-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144265-A1 | HIV protease inhibitors based on amino acid derivatives | ANPEP, PEPD, XPNPEP1 | ATM 3061/4885L3MBTL1 2747/4885MAPT 2981/4885 |
| US-20020151546-A1 | HIV protease inhibitors based on amino acid derivatives | ANPEP, PEPD, XPNPEP1 | ATM 3061/4885L3MBTL1 2747/4885MAPT 2981/4885 |
| US-20030195159-A1 | HIV protease inhibitors based on amino acid derivatives | ANPEP, PEPD, XPNPEP1 | ATM 3061/4885L3MBTL1 2747/4885MAPT 2981/4885 |
| US-20030119803-A1 | HIV protease inhibitors based on amino acid derivatives | ANPEP, PEPD, XPNPEP1 | ATM 3061/4885L3MBTL1 2747/4885MAPT 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.